TY - JOUR
T1 - Reconstituted HDL
T2 - Drug delivery platform for overcoming biological barriers to cancer therapy
AU - Raut, Sangram
AU - Mooberry, Linda
AU - Sabnis, Nirupama
AU - Garud, Ashwini
AU - Dossou, Akpedje Serena
AU - Lacko, Andras
N1 - Funding Information:
The author's research was supported by Cancer Prevention and Research Institute of Texas (DP150091), Rutledge Cancer Foundation, Wheels for Wellness of Fort Worth, Texas, to Andras Lacko. This work in part was supported by Texas Alzheimer's Research Care and Consortium (2018-48-51-JI) and Leukemia Texas Foundation grants to SR.
Funding Information:
The author’s research was supported by Cancer Prevention and Research Institute of Texas (DP150091), Rutledge Cancer
Publisher Copyright:
Copyright © 2018 Raut, Mooberry, Sabnis, Garud, Dossou and Lacko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PY - 2018/10/15
Y1 - 2018/10/15
N2 - Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, “nature's drug delivery system,” while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.
AB - Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, “nature's drug delivery system,” while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.
KW - Biological barriers
KW - Cancer therapy and imaging
KW - Cholesterol
KW - HDL
KW - RHDL
KW - SR-B1 receptor
KW - Tumor targeting
UR - http://www.scopus.com/inward/record.url?scp=85055279498&partnerID=8YFLogxK
U2 - 10.3389/fphar.2018.01154
DO - 10.3389/fphar.2018.01154
M3 - Review article
AN - SCOPUS:85055279498
SN - 1663-9812
VL - 9
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
IS - OCT
M1 - 1154
ER -